EP2889032A4 - Composition pour la prévention ou le traitement d'une maladie rénale comprenant un dérivé de pyrazole - Google Patents

Composition pour la prévention ou le traitement d'une maladie rénale comprenant un dérivé de pyrazole

Info

Publication number
EP2889032A4
EP2889032A4 EP13834243.1A EP13834243A EP2889032A4 EP 2889032 A4 EP2889032 A4 EP 2889032A4 EP 13834243 A EP13834243 A EP 13834243A EP 2889032 A4 EP2889032 A4 EP 2889032A4
Authority
EP
European Patent Office
Prior art keywords
preventing
composition
kidney disease
pyrazole derivative
treating kidney
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP13834243.1A
Other languages
German (de)
English (en)
Other versions
EP2889032B1 (fr
EP2889032A1 (fr
Inventor
Yun Soo Bae
Hun Joo Ha
Kee In Lee
Kyung Hee Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Collaboration Foundation of Ewha University
Original Assignee
Industry Collaboration Foundation of Ewha University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Collaboration Foundation of Ewha University filed Critical Industry Collaboration Foundation of Ewha University
Priority to PL13834243T priority Critical patent/PL2889032T3/pl
Publication of EP2889032A1 publication Critical patent/EP2889032A1/fr
Publication of EP2889032A4 publication Critical patent/EP2889032A4/fr
Application granted granted Critical
Publication of EP2889032B1 publication Critical patent/EP2889032B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP13834243.1A 2012-08-27 2013-08-02 Composition pour la prévention ou le traitement d'une maladie rénale comprenant un dérivé de pyrazole Active EP2889032B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL13834243T PL2889032T3 (pl) 2012-08-27 2013-08-02 Kompozycja zawierająca pochodną pirazolu do zapobiegania lub leczenia choroby nerek

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120093936A KR101633957B1 (ko) 2012-08-27 2012-08-27 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물
PCT/KR2013/006985 WO2014035070A1 (fr) 2012-08-27 2013-08-02 Composition pour la prévention ou le traitement d'une maladie rénale comprenant un dérivé de pyrazole

Publications (3)

Publication Number Publication Date
EP2889032A1 EP2889032A1 (fr) 2015-07-01
EP2889032A4 true EP2889032A4 (fr) 2016-03-09
EP2889032B1 EP2889032B1 (fr) 2019-05-08

Family

ID=50183832

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13834243.1A Active EP2889032B1 (fr) 2012-08-27 2013-08-02 Composition pour la prévention ou le traitement d'une maladie rénale comprenant un dérivé de pyrazole

Country Status (9)

Country Link
US (1) US10047067B2 (fr)
EP (1) EP2889032B1 (fr)
JP (1) JP5974180B2 (fr)
KR (1) KR101633957B1 (fr)
CN (1) CN104755077B (fr)
ES (1) ES2734264T3 (fr)
PL (1) PL2889032T3 (fr)
TR (1) TR201909923T4 (fr)
WO (1) WO2014035070A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101826208B1 (ko) 2016-02-05 2018-02-06 경북대학교 산학협력단 뉴로펩타이드 y를 유효성분으로 포함하는, 신장질환의 예방 또는 치료용 약학적 조성물
KR101856444B1 (ko) * 2017-04-20 2018-05-10 압타바이오 주식회사 3-페닐-4-프로필-1-(피리딘-2-일)-1ｈ-피라졸-5-올 염산염의 신규 결정형 고체 화합물
KR101840702B1 (ko) 2017-11-01 2018-03-22 압타바이오 주식회사 간질환 치료제
JP7470791B2 (ja) 2019-11-21 2024-04-18 サムジン ファーマシューティカル カンパニー，リミテッド 眼疾患の予防または治療用点眼組成物
KR102277665B1 (ko) * 2020-02-05 2021-07-15 바이오그래핀 주식회사 그래핀 기반 신장 질환 치료용 조성물
CA3172610A1 (fr) * 2020-04-08 2021-10-14 Soo Jin Lee Agent pour le traitement d'une lesion renale aigue induite par produit de contraste
KR102308991B1 (ko) * 2020-04-08 2021-10-06 압타바이오 주식회사 조영제 유발 급성 신부전 치료제
KR102386097B1 (ko) * 2020-04-13 2022-04-14 압타바이오 주식회사 피라졸 유도체의 폐섬유증 치료제
EP4137134A1 (fr) * 2020-04-13 2023-02-22 Aptabio Therapeutics Inc. Médicament contre la fibrose pulmonaire contenant un dérivé de pyrazole
KR102589130B1 (ko) 2021-03-24 2023-10-13 삼진제약주식회사 N-옥소 피리딘 화합물 발생을 억제하는 안질환 예방 또는 치료용 점안 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003335672A (ja) * 2002-05-20 2003-11-25 Ajinomoto Co Inc 線維化病変組織修復剤
EP1900728A1 (fr) * 2005-05-30 2008-03-19 Genecare Research Institute Co., Ltd Préparation pharmaceutique comprenant un dérivé de pyrazolone
WO2009119987A2 (fr) * 2008-03-25 2009-10-01 이화여자대학교 산학협력단 Composition comprenant des dérivés de pyrazole pouvant prévenir ou traiter l'ostéoporose
KR20110025149A (ko) * 2009-09-02 2011-03-09 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4023488A1 (de) * 1990-07-24 1992-01-30 Bayer Ag 1-(pyri(mi)dyl-(2)) -5-hydroxy-pyrazol-mikrobizide
AU2697092A (en) 1991-10-08 1993-05-03 Nippon Soda Co., Ltd. Pyrazole derivative and agrohorticultural bactericide containing same
JP2003098120A (ja) 2001-09-26 2003-04-03 Tokyo Weld Co Ltd 外観検査装置
KR20040094464A (ko) 2003-05-02 2004-11-10 학교법인 이화학당 피리디닐 피라졸 유도체
JP5121717B2 (ja) 2006-09-01 2013-01-16 大塚アグリテクノ株式会社 Ｎ−ピリジルピペリジン化合物、その製造方法及び有害生物防除剤
US8637674B2 (en) 2009-09-02 2014-01-28 Ewha University-Industry Collaboration Foundation Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003335672A (ja) * 2002-05-20 2003-11-25 Ajinomoto Co Inc 線維化病変組織修復剤
EP1900728A1 (fr) * 2005-05-30 2008-03-19 Genecare Research Institute Co., Ltd Préparation pharmaceutique comprenant un dérivé de pyrazolone
WO2009119987A2 (fr) * 2008-03-25 2009-10-01 이화여자대학교 산학협력단 Composition comprenant des dérivés de pyrazole pouvant prévenir ou traiter l'ostéoporose
KR20110025149A (ko) * 2009-09-02 2011-03-09 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; March 2006 (2006-03-01), QIAO YU-FENG ET AL: "[Expression of renal nuclear factor-kappaB, transforming growth factor-beta and fibronectin of rats exposed to lead].", XP002753384, Database accession no. NLM16600131 *
See also references of WO2014035070A1 *
ZHONGHUA LAO DONG WEI SHENG ZHI YE BING ZA ZHI = ZHONGHUA LAODONG WEISHENG ZHIYEBING ZAZHI = CHINESE JOURNAL OF INDUSTRIAL HYGIENE AND OCCUPATIONAL DISEASES MAR 2006, vol. 24, no. 3, March 2006 (2006-03-01), pages 139 - 142, ISSN: 1001-9391 *

Also Published As

Publication number Publication date
WO2014035070A1 (fr) 2014-03-06
JP5974180B2 (ja) 2016-08-23
TR201909923T4 (tr) 2019-07-22
CN104755077B (zh) 2018-05-15
JP2015531774A (ja) 2015-11-05
KR20140027833A (ko) 2014-03-07
US20150218125A1 (en) 2015-08-06
KR101633957B1 (ko) 2016-06-27
EP2889032B1 (fr) 2019-05-08
ES2734264T3 (es) 2019-12-05
CN104755077A (zh) 2015-07-01
PL2889032T3 (pl) 2019-09-30
EP2889032A1 (fr) 2015-07-01
US10047067B2 (en) 2018-08-14

Similar Documents

Publication Publication Date Title
PL2889032T3 (pl) Kompozycja zawierająca pochodną pirazolu do zapobiegania lub leczenia choroby nerek
IL253441A0 (en) A medicine for the prevention and/or treatment of polycystic kidney disease
HK1209585A1 (en) Vermin controlling agent
HRP20160804T1 (hr) Spojevi pirazola kao inhibitori sglt1
HK1213253A1 (zh) 新型吡唑衍生物
HK1210969A1 (en) Substituted heterocyclic compounds for disease treatment
HK1207579A1 (en) Composition for preventing or treating heart disease
SG11201500211PA (en) Composition for preventing or treating osteoarthritis
EP2823825A4 (fr) Composition pharmaceutique pour traiter le cancer
EP2886122A4 (fr) Agent pour le traitement du cancer
ZA201507015B (en) Composition for treating hemorrhoids
EP2563353A4 (fr) Composés pour traitement antifongique
GB201216373D0 (en) Appetite-suppressant composition
EP2928461A4 (fr) Traitement pour maladie rénale chronique
AU344960S (en) Sideboard
GB201219296D0 (en) Pyrazole derivatives
GB201219289D0 (en) Pyrazole derivatives
GB201218245D0 (en) Pyrazole derivatives
GB201214172D0 (en) Mr Karl Hunter

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150327

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 403/04 20060101ALI20160128BHEP

Ipc: C07D 405/14 20060101ALI20160128BHEP

Ipc: A61K 31/506 20060101ALI20160128BHEP

Ipc: A61K 31/41 20060101ALI20160128BHEP

Ipc: A61K 31/4155 20060101AFI20160128BHEP

Ipc: A61P 13/12 20060101ALI20160128BHEP

Ipc: A61K 31/4439 20060101ALI20160128BHEP

Ipc: C07D 401/04 20060101ALI20160128BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160205

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170908

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 413/14 20060101ALI20181119BHEP

Ipc: C07D 403/04 20060101ALI20181119BHEP

Ipc: A61P 13/12 20060101ALI20181119BHEP

Ipc: A61K 31/4155 20060101AFI20181119BHEP

Ipc: A61K 31/41 20060101ALI20181119BHEP

Ipc: C07D 405/14 20060101ALI20181119BHEP

Ipc: A61K 31/506 20060101ALI20181119BHEP

Ipc: A61K 31/4439 20060101ALI20181119BHEP

Ipc: C07D 401/04 20060101ALI20181119BHEP

INTG Intention to grant announced

Effective date: 20181204

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1129093

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190515

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013055198

Country of ref document: DE

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: NOVAGRAAF INTERNATIONAL SA, CH

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20190402034

Country of ref document: GR

Effective date: 20191016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190908

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190808

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190808

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2734264

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20191205

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1129093

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013055198

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20200211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190802

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190802

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190908

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20130802

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190508

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230718

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230801

Year of fee payment: 11

Ref country code: IT

Payment date: 20230711

Year of fee payment: 11

Ref country code: GB

Payment date: 20230706

Year of fee payment: 11

Ref country code: ES

Payment date: 20230908

Year of fee payment: 11

Ref country code: CH

Payment date: 20230902

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20230712

Year of fee payment: 11

Ref country code: GR

Payment date: 20230713

Year of fee payment: 11

Ref country code: FR

Payment date: 20230710

Year of fee payment: 11

Ref country code: DE

Payment date: 20230705

Year of fee payment: 11

Ref country code: BE

Payment date: 20230719

Year of fee payment: 11